- ASX
Sigma Pharmaceuticals Ltd
Healthcare AU SIG
2.89AUD
-(-%)
Last update at 2025-04-04T05:53:00Z
Day Range
52 Week Range
Fundamentals
- Previous Close 2.89
- Market Cap33592.17M
- Volume28792966
- P/E Ratio-
- Dividend Yield0.36%
- EBITDA29.36M
- Revenue TTM3480.61M
- Revenue Per Share TTM2.41
- Gross Profit TTM 227.81M
- Diluted EPS TTM-0.01
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Analyst Recommendations
-
Is Sigma Healthcare Limited (ASX:SIG) Trading At A 44% Discount?
1 year, 3 months ago -
Sigma Healthcare (ASX:SIG) Might Be Having Difficulty Using Its Capital Effectively
1 year, 6 months ago -
Sigma Healthcare (ASX:SIG) shareholders have earned a 48% return over the last year
1 year, 10 months ago -
Investors Could Be Concerned With Sigma Healthcare's (ASX:SIG) Returns On Capital
1 year, 11 months ago
Financials
Income Statement
Balancesheet
Change in Cash
Total Operating Cash
Dividends Paid
| Breakdown | 2023-01-31 | 2022-01-31 | 2021-01-31 | 2020-01-31 | 2019-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-01-31 | 2022-01-31 | 2021-01-31 | 2020-01-31 | 2019-01-31 |
| Income before tax | 5.46M | -8.30700M | 51.75M | -15.76000M | 51.96M |
| Minority interest | -1.21600M | -0.90300M | 0.69M | 0.79M | 1.03M |
| Net income | 3.03M | -6.33600M | 59.76M | -11.46700M | 36.52M |
| Selling general administrative | 82.62M | 93.02M | 68.79M | 67.98M | 63.60M |
| Selling and marketing expenses | 210.38M | 216.58M | 214.61M | 220.95M | 232.50M |
| Gross profit | 320.63M | 296.51M | 289.06M | 269.60M | 312.69M |
| Reconciled depreciation | 30.34M | 27.69M | 30.99M | 27.26M | 13.52M |
| Ebit | 26.86M | 4.18M | 34.20M | -1.17400M | 63.28M |
| Ebitda | 57.19M | 31.87M | 65.19M | 26.08M | 76.81M |
| Depreciation and amortization | 30.34M | 27.69M | 30.99M | 27.26M | 13.52M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 26.86M | 4.18M | 34.20M | -1.17400M | 3.07M |
| Other operating expenses | 3735.65M | 3556.35M | 3475.58M | 3345.43M | 4013.20M |
| Interest expense | 14.41M | 10.84M | 11.82M | 13.44M | 11.85M |
| Tax provision | 2.44M | -1.97100M | -9.50400M | -4.29300M | 14.92M |
| Interest income | 0.60M | 0.22M | 11.46M | 12.70M | 11.07M |
| Net interest income | -13.81000M | -10.62000M | -11.46300M | -12.70200M | -11.07000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 2.44M | -1.97100M | -9.50400M | -4.29300M | 14.92M |
| Total revenue | 3726.46M | 3515.56M | 3450.24M | 3298.84M | 4016.27M |
| Total operating expenses | 329.82M | 337.29M | 314.39M | 316.18M | 309.62M |
| Cost of revenue | 3405.83M | 3219.06M | 3161.19M | 3029.24M | 3703.58M |
| Total other income expense net | -21.39600M | -12.48800M | 17.54M | -14.58600M | 48.88M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 3.03M | -6.33600M | 61.25M | -11.46700M | 37.04M |
| Net income applicable to common shares | 1.81M | -7.23900M | 59.76M | -12.33000M | 36.52M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 | 2021-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 | 2021-01-31 |
| Total assets | 1830.57M | 1404.13M | 1174.07M | 1248.28M | 1205.62M |
| Intangible assets | 19.65M | 20.00M | 22.90M | 25.09M | 55.10M |
| Earning assets | - | - | - | - | - |
| Other current assets | 26.06M | 14.91M | 11.87M | 50.17M | 9.63M |
| Total liab | 991.29M | 531.52M | 696.31M | 759.50M | 670.71M |
| Total stockholder equity | 837.86M | 870.77M | 475.92M | 487.19M | 534.22M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 126.77M | 57.99M | 57.45M | 77.76M | 82.32M |
| Common stock | 1641.07M | 1682.37M | 1234.46M | 1225.45M | 1219.91M |
| Capital stock | 1641.07M | 1637.02M | 1234.46M | 1225.45M | 1219.91M |
| Retained earnings | -799.52900M | -769.17600M | -761.58700M | -741.13400M | -690.92300M |
| Other liab | - | - | 4.91M | 4.15M | 7.24M |
| Good will | 89.06M | 89.06M | 95.22M | 102.96M | 102.96M |
| Other assets | - | - | 61.68M | 59.40M | 41.77M |
| Cash | 14.57M | 356.50M | 16.65M | 31.14M | 16.13M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 864.97M | 371.28M | 477.36M | 457.61M | 523.66M |
| Current deferred revenue | 1.17M | 0.14M | 0.96M | 1.89M | 0.46M |
| Net debt | 117.51M | -219.86500M | 210.34M | 292.29M | 199.10M |
| Short term debt | 10.64M | 9.79M | 12.94M | 25.69M | 75.41M |
| Short long term debt | - | - | 3.68M | 15.38M | 66.38M |
| Short long term debt total | 132.09M | 136.63M | 226.99M | 323.43M | 215.23M |
| Other stockholder equity | - | -45.34900M | 0.22M | 2.87M | 5.23M |
| Property plant equipment | - | - | 290.92M | 281.56M | 288.29M |
| Total current assets | 1376.79M | 912.50M | 685.85M | 761.63M | 702.20M |
| Long term investments | 8.52M | 13.62M | 16.08M | 17.63M | 15.30M |
| Net tangible assets | - | - | 357.68M | 359.14M | 376.16M |
| Short term investments | - | - | 0.00000M | 0.01M | 0.00000M |
| Net receivables | 952.72M | 319.96M | 332.48M | 358.68M | 327.30M |
| Long term debt | - | - | 80.00M | 165.00M | 0.00000M |
| Inventory | 383.44M | 221.13M | 324.85M | 321.64M | 349.14M |
| Accounts payable | 726.38M | 303.36M | 406.01M | 352.27M | 365.47M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3.68000M | 2.92M | 3.04M | 2.87M | 5.23M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 1219.91M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 38.73M | 1.19M | 1.31M | 0.78M | 1.43M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 453.78M | 491.63M | 488.23M | 486.65M | 503.42M |
| Capital lease obligations | 132.09M | 136.63M | 143.30M | 143.06M | 148.85M |
| Long term debt total | - | - | 214.04M | 297.74M | 139.82M |
| Breakdown | 2023-01-31 | 2022-01-31 | 2021-01-31 | 2020-01-31 | 2019-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-01-31 | 2022-01-31 | 2021-01-31 | 2020-01-31 | 2019-01-31 |
| Investments | -28.60400M | -2.38700M | -6.33200M | -7.14500M | -3.02500M |
| Change to liabilities | 53.54M | -7.11200M | 5.14M | -133.18400M | -33.70700M |
| Total cashflows from investing activities | -28.60400M | -16.59200M | 98.76M | -68.44000M | -101.60600M |
| Net borrowings | -101.88000M | 148.62M | -264.56400M | -77.20800M | 119.99M |
| Total cash from financing activities | -116.94100M | 128.89M | -265.71100M | -100.56600M | 83.47M |
| Change to operating activities | 16.64M | -51.52300M | 6.69M | 8.23M | -6.63700M |
| Net income | 3.03M | -7.23900M | 59.76M | -11.46700M | 36.52M |
| Change in cash | -2.80100M | 66.02M | -154.48300M | 31.62M | -9.63900M |
| Begin period cash flow | 15.77M | -50.25100M | 104.23M | 72.61M | 82.25M |
| End period cash flow | 12.97M | 15.77M | -50.25100M | 104.23M | 72.61M |
| Total cash from operating activities | 33.36M | 27.69M | 12.47M | 200.62M | 8.47M |
| Issuance of capital stock | 0.88M | 0.20M | 0.49M | 5.28M | 8.61M |
| Depreciation | 30.34M | 27.69M | 30.99M | 27.26M | 13.52M |
| Other cashflows from investing activities | 0.80M | -0.00100M | 175.80M | -11.29600M | 6.56M |
| Dividends paid | 15.94M | 19.93M | 1.59M | 30.71M | 40.98M |
| Change to inventory | -3.21100M | 27.50M | -33.64500M | 27.78M | 7.20M |
| Change to account receivables | 27.50M | -30.73200M | -30.92500M | 285.75M | -11.79600M |
| Sale purchase of stock | 0.88M | 0.20M | -0.05000M | -0.05000M | -4.14400M |
| Other cashflows from financing activities | -16.88000M | 148.62M | -14.56400M | -9.78000M | 119.99M |
| Change to netincome | 23.43M | 9.39M | -20.82400M | 6.33M | 1.73M |
| Capital expenditures | 29.40M | 14.20M | 77.03M | 57.14M | 108.16M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.60M | 0.22M | 0.36M | 0.74M | 0.78M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -33.36300M | -20.45200M | -90.74900M | -14.92800M | -50.04200M |
| Free cash flow | 3.96M | 13.49M | -64.56100M | 143.48M | -99.69300M |
Peer Comparison
Sector: Healthcare Industry: Medical Distribution
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SIG Sigma Pharmaceuticals Ltd |
- -% | 2.89 | - | 60.98 | 9.65 | 39.82 | 6.84 | 603.53 |
| EBO EBOS Group Ltd |
0.03 0.08% | 35.69 | 25.15 | 28.33 | 0.54 | 2.79 | 0.64 | 14.17 |
| PGC Paragon Care Ltd |
- -% | 0.40 | 39.20 | 5.98 | 0.19 | 2.13 | 0.20 | 11.92 |
| CYC Cyclopharm Ltd |
-0.06 4.84% | 1.18 | - | 116.28 | 4.76 | 3.23 | 4.55 | -24.5712 |
Reports Covered
Profile
Sigma Healthcare Limited, together with its subsidiaries, engages in the wholesale distribution of pharmaceutical goods and medical consumables to community pharmacies primarily in Australia. The company operates various aligned pharmacies, including branded pharmacies under the Amcal, Discount Drug Stores, Guardian, and PharmaSave brands. It also provides retail support services to its branded network of pharmacy members; dose administration aid services; and third and fourth-party logistics services to pharmaceutical manufacturers and other supplier partners. The company was founded in 1912 and is headquartered in Clayton, Australia.
Sigma Pharmaceuticals Ltd
2125 Dandenong Road, Clayton, VIC, Australia, 3168
- 61 3 9215 9215
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Vikesh Ramsunder B.Com. | CEO, MD & Director | 1971 |
| Mr. Nigel Simonsz | Chief Financial Officer | NA |
| Mr. Martin Hawkins | Chief Information Officer | NA |
| Ms. Kara McGowan | Company Sec. & Gen. Counsel | NA |
| Mr. Mark Conway B.Com., M.B.A. | Chief Financial Officer | NA |
| Ms. Kara McGowan A.C.I.S., L.L.B. | Company Secretary & General Counsel | NA |
| Mr. Gary Woodford | Head of Corporate Affairs | NA |
| Mr. Mark Conway B.Com., M.B.A. | Chief Financial Officer | NA |
| Ms. Kara McGowan A.C.I.S., L.L.B. | Company Secretary & General Counsel | NA |
| Mr. Gary Woodford | Head of Corporate Affairs | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
